Skip to main content

Novoeight FDA Approval History

FDA Approved: Yes (First approved October 15, 2013)
Brand name: Novoeight
Generic name: turoctocog alfa
Dosage form: for Intravenous Injection
Company: Novo Nordisk
Treatment for: Hemophilia A

Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated for use in adults and children with hemophilia A.

Development timeline for Novoeight

Oct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.